Millennials and baby boomers have a lot of common: a desire for technology that supports health priorities.
Search queries for common diseases on the websites for the CDC and WebMD, among others, are being sent to third-party corporations.
FDA approves Novartis's Farydak for multiple myeloma; Shire acquires rare-disease drug for $70 million; FTC fines melanoma app marketers.
A treatise on understanding the FDA's latest guidance of low-risk general wellness products.
Lilly delays Phase-III cholesterol drug results; PatientsLikeMe and Walgreens team up for "drug reaction reviews"; Roche skin-cancer drug receives Priority Review.
How the adoption of principles from recent, successful start ups can be applied to pharma marketing.
Citing an unnamed source, the paper reports that Apple has abandoned some of the more advanced health monitoring features in its upcoming device, the Apple Watch.
Doximity professional network now includes financial data; Pfizer settles class-action lawsuit; researchers hope to use temporary tattoos to identify glucose levels.
The nighttime sleep aid's Twitter account wrote "Sleep LIKE he finally proposed," last week, a sentiment which didn't resonate positively with the feed's followers.
Google teams up with PwC for DOD EHR project bid; FDA approves first weight-loss device since 2007; research says opioid abuse may be on the decline.
Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.